Mumbai: Russia has stated that its Sputnik V vaccine 19 has shown 92 percent efficacy against COVID19 disease caused by a coronavirus. Moscow said the confirmation is based on the first interim data from 40,000 volunteers from one of the largest double-blind, randomized, placebo-controlled Phase 3 clinical trials in Russia.
US drug giant Pfizer and its partner German firm BioNotech announced that their mRNA-based coronavirus vaccine candidate, BNT162b2, was found to be more than 90 percent effective against the SARS-CoV-2 virus.
In the name of the National Research Center for Epidemiology and Microbiology, Russia’s Ministry of Health’s NA Gamalaya (Gamalaya Center) and the Russian Direct Investment Fund (RDIF), Russia’s Sovereign Wealth Fund, announced in a press release on Tuesday that efficacy. Was performed based on the first interim analysis obtained 21 days after the first dose of the vaccine. As part of the research, no unexpected adverse events were identified on 11 November during vaccine trials.
In the name of the National Research Center for Epidemiology and Microbiology, Russia’s Ministry of Health’s NA Gamalaya (Gamalaya Center) and the Russian Direct Investment Fund (RDIF), Russia’s Sovereign Wealth Fund, announced in a press release on Tuesday that efficacy. Was performed based on the first interim analysis obtained 21 days after the first dose of the vaccine. As part of the research, no unexpected adverse events were identified on 11 November during vaccine trials.
Also Read: Pfizer Says Its COVID-19 Vaccine Is More Than 90% Effective
“The publication of interim results of post-registration clinical trials that clearly demonstrate the efficacy of the Sputnik V vaccine gives way to mass vaccination against COVID-19 in Russia in the coming weeks. Thanks to the production scale-up at new manufacturing sites, the Sputnik V vaccine will soon be available for a wider population. This will break the current trend and lead to an eventual decrease in COVID-19 infection rates, first in Russia, then globally,” Alexander Gintsburg, Gamaleya Center Director, said.
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform. The Gamaleya Center team would publish the interim research data in one of the leading international peer-reviewed medical journals.
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
